Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study

Real-world evidence plays an important role in the assessment of efficacy and safety of novel therapies. The increasing use of immune checkpoint inhibitors (ICIs) in patients with advanced melanoma has led to notably improved clinical outcomes, while they are also associated with immune-related adve...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuzmanovszki, Daniella, Kiss, Norbert, Tóth, Béla, Kerner, Tünde, Tóth, Veronika, Szakonyi, József, Lőrincz, Kende, Hársing, Judit, Imrédi, Eleonóra, Pfund, Alexa, Szabó, Ákos, Brodszky, Valentin, Rencz, Fanni, Holló, Péter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313334/
https://www.ncbi.nlm.nih.gov/pubmed/35885042
http://dx.doi.org/10.3390/biomedicines10071737

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313334/
https://www.ncbi.nlm.nih.gov/pubmed/35885042
http://dx.doi.org/10.3390/biomedicines10071737

Ejemplares similares